SUZHOU, China

中国苏州

,

，

Aug. 31, 2026

2026年8月31日

/PRNewswire/ --

/美通社/ --

Convergen, a biotechnology company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a $15 million Seed+ financing round. This round was led by MPCi, with participation from LAV, BioTrack Capital and a leading biotech fund.

Convergen 是一家致力于开发针对由病理性蛋白聚集驱动疾病的靶向蛋白降解（TPD）疗法的生物技术公司，今日宣布完成 1500 万美元的 Seed+ 轮融资。本轮融资由 MPCi 领投，LAV、BioTrack Capital 以及一家领先的生物技术基金参与投资。

Prior to this round, the company raised $10 million in a seed financing .

在本轮融资之前，该公司在种子轮融资中筹集了1000万美元。

round

轮次

led exclusively by Qiming Venture Partners.

由启明创投独家领投。

The proceeds will be used to further advance Convergen's proprietary degrader platform and accelerate its pipeline for neurodegenerative disorders and other protein aggregation diseases.

所得款项将用于进一步推进 Convergen 的专有降解剂平台，并加速其在神经退行性疾病及其他蛋白质聚集疾病领域的管线开发。

'We are grateful to the distinguished group of investors and their confidence in our science, platform and team,' said Dr. Jinquan Sun, CEO of Convergen. 'We have made significant progress in advancing our protein degradation platform. This financing will enable us to accelerate our lead asset toward the clinic while continuing to advance our pipeline, with the goal of bringing new therapeutic options to patients with neurodegenerative diseases and beyond.'.

Convergen 首席执行官孙金泉博士表示：“我们感谢这群杰出的投资者，并感谢他们对我们科学、平台及团队的信任。我们在推进蛋白质降解平台方面已取得显著进展。此次融资将使我们能够加速推动我们的首要资产进入临床试验，同时继续推进我们的产品管线，旨在为神经退行性疾病及其他疾病患者带来新的治疗选择。”

Addressing a Critical Unmet Need

解决尚未满足的关键需求

Neurodegenerative diseases such as Alzheimer's represent one of the largest unmet medical needs globally, with pathologic protein aggregation at the core. Convergen's scientific founder Prof. Ting Han, whose laboratory reported the first TRIM21 molecular glue, established the proof-of-concept of the first TrimTAC degrader (November 2024 in .

阿尔茨海默病等神经退行性疾病以病理性蛋白质聚集为核心，是全球尚未满足的最大医疗需求之一。Convergen公司的科学创始人韩婷教授，其实验室报告了首个TRIM21分子胶，并确立了首个TrimTAC降解剂的概念验证（2024年11月）。

Cell

细胞

) which targets

）针对

protein aggregopathies

蛋白质聚集病

by exploiting TRIM21's unique property. Beyond neurodegeneration, TrimTAC has demonstrated potential in selectively degrading other targets for autoimmune

通过利用TRIM21的独特特性。除了神经退行性疾病外，TrimTAC在选择性降解自身免疫疾病的其他靶点方面也显示出潜力。

diseases

疾病

.

。

MPCi said:

MPCi 表示：

'Convergen's degrader platform is truly differentiated in the targeted protein degradation landscape. Matrix Partners China has long adhered to an investment philosophy of 'investing early, investing in high barriers, and investing in differentiation,' with a focus on the application potential of breakthrough technology platforms across disease areas.

Convergen的降解平台在靶向蛋白降解领域具有真正的差异化优势。经纬中国长期秉持“投早、投高壁垒、投差异化”的投资理念，重点关注突破性技术平台在各疾病领域的应用潜力。

We are highly confident in the extensibility of Convergen's original platform and in the team's ability to translate scientific discovery into clinical drugs. We look forward to partnering with the company to advance novel therapeutic options to patients worldwide.'.

我们对Convergen原始平台的可扩展性以及团队将科学发现转化为临床药物的能力充满信心。我们期待与该公司合作，为全球患者推进创新的治疗方案。

About Convergen

关于 Convergen

Convergen is a biotechnology company pioneering the next-generation targeted protein degradation technology designed to selectively eliminate pathological protein aggregates. Founded to address the significant unmet medical needs in neurodegenerative disease and beyond, the company combines cutting-edge academic research with industry-proven drug development expertise..

Convergen 是一家生物技术公司，致力于开创下一代靶向蛋白降解技术，旨在选择性清除病理性蛋白聚集体。公司成立的初衷是应对神经退行性疾病及其他领域尚未满足的重大医疗需求，将前沿的学术研究与经行业验证的药物开发专业知识相结合。

SOURCE Convergen

来源 Convergen

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示